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ABSTRACT
The 5-hydroxytryptamine (5-HT1A) receptors represent an attractive target in drug discovery. In particular,
5-HT1A agonists and partial agonists are deeply investigated for their potential role in the treatment of
anxiety, depression, ischaemic brain disorder and more recently, of pain. On the other hand, 5-HT1A antag-
onists have been revealed promising compounds in cognition disorders and, lately, in cancer. Thus, the
discovery of 5HT1A ligands is nowadays an appealing research activity in medicinal chemistry. In this work,
Comparative Molecular Fields Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis
(CoMSIA) were applied on an in-house library of 5-HT1A ligands bearing different chemical scaffolds in
order to elucidate their affinity and selectivity for the target. Following this procedure, a number of struc-
tural modifications have been drawn for the development of much more effective 5-HT1AR ligands.
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Introduction
Serotonin (5-hydroxytryptamine, 5-HT) represents a key neurotrans-
mitter playing a fundamental role especially at the central nervous
system (CNS), being involved in numerous behavioural processes,
such as anxiety, mood, aggression, addictive behaviours, as well as
memory and learning processes, sleep, thermoregulation, appetite,
emesis, thalamic blood pressure, nociception and migraine head-
aches1. Up to now, at least 14 receptor subtypes (5-HT1 to 5-HT7)
have been identified and therefore classified in terms of amino
acid sequence and biological function. Among them, the 5-HT1A
receptor was the first one to be identified and pharmacologically
investigated, relying on a number of ligands employed as pharma-
cological tools, such as BMY-7378 and WAY-1006352,3 (Figure 1).
From a pharmaceutical point of view, the most interesting thera-
peutic potential of 5-HT1A agonists and partial agonists revolves
around the treatment of anxiety, depression, ischaemic brain dis-
order and, more recently, in pain3–5. On the contrary antagonists of
this receptor proved to be promising in cognition disorders, like
Alzheimer’s disease therapy6 and, lately, in cancer7.
On the other hand, due to the high pairwise similarity percent-
age between 5-HT1AR and a1-adrenoreceptor (ADRs), a number of
5-HT1A ligands proved to efficiently bind also to ADRs, at the
expense of selectivity, as shown for instance in Figure 1 around
the references BMY-7378 and WAY-100635. The a1 adrenergic
receptors (a1-ADRs) are deeply involved in the modulation of the
activity of the sympathetic nervous system, becoming relevant
druggable targets for many therapeutic agents. a1-ADRs are classi-
fied into at least three subtypes named a1A, a1B and a1D.
Antagonists of these receptors have been initially introduced for
hypertension management, being later explored also for the treat-
ment of benign prostatic hyperplasia (BPH)8.
During the last years, we focussed our attention on the
development of new classes of potent 5-HT1A receptor ligands,
including 1,3-dioxolane-, 1,3-oxathiolane-, 1,3-dithiolane-, spiro-
dioxolane-tetrahydrofuran-, cyclopentanone- and cyclopentanol-
based derivatives, whose 5-HT1A versus ADRs selectivity profiles
were variable being in particular overall lower those towards the
a1D subtype
9–15. Here, with the aim of further exploring the key
requirements to enhance the serotoninergic affinity and selectivity
over a1D ADR, a three-dimensional quantitative structure–activity
relationship (3D-QSAR) ligand-based computational protocol was
applied to the aforementioned in-house library of compounds. In
particular, we performed Comparative Molecular Fields Analysis
(CoMFA) and a Comparative Molecular Similarity Index Analysis
(CoMSIA), which represent useful tools to investigate the affinity
as well as the selectivity profiles of compounds16–22.
The role played by steric, electrostatic, H-bond acceptor and
donor and hydrophobic features with respect to the 5-HT1A affinity
and selectivity trends observed within the library of ligands
suggested some structural modifications which could be useful for
the development of new chemical scaffolds with an improved
affinity and selectivity profile for 5-HT1A receptor. The reliability of
the final models was consistent with the effectiveness of an exter-
nal series of 5-HT1A ligands, giving a further validation of the
3D-QSAR studies here discussed. Moreover the results allowed us
to derive robust statistical models to be used to predict the affin-
ity of new analogues prior to synthesis and therefore to pave the
way for the further design of more promising derivatives.
Methods
Dataset
In this work, the employed dataset included 81 compounds
already synthesised by some of us (compounds 1–91)10–15. These
molecules were divided into two groups according to the different
linker between the five-membered ring and the terminal aromatic
moiety of the scaffold, as shown in Tables 1 and 2. Group A
(1–42; Table 1) included flexible open linker derivatives, while
Group B (43–91; Table 2) contained all the piperazine ones. Tables
1 and 2 are also listed the 5HT-1A pKi and the a1D pKi. Any details
concerning the biological assays performed to evaluate the com-
pounds affinity towards 5HT-1A receptors and ADRs have been
reported in the previously cited works.
Any compound was built, parameterised (Gasteiger-H€uckel
method) and energy minimised within MOE using MMFF94 force
field23.
Notably, since all the analysed compounds displayed at least
one chiral carbon atom, the selection of the most proper enantio-
mer was required for the further ligand-based studies. As far as
we knew from our previous experimental studies on enantiomeric
resolution of compound 1, the stereoselectivity of the derivative
was poor being (S)-1 5-HT1A pKi¼ 8.42 and (R)-1 5-HT1A
pKi¼ 8.5224.
For this reason, we considered to rely on these data and there-
fore to select for the in silico design (and alignment) those enan-
tiomers along the whole dataset which proved to be also
recommended by our docking results, as we previously
detailed12,14,15.
Briefly, within both Group A and B diphenyl-substituted dioxo-
lane compounds were selected as cR enantiomers (as suggested
by the enantiomeric resolution of (1) as well as for the tetrahydro-
furans and cyclopentanones, while the cis and trans mono-phenyl
substituted ones followed the preferred aS,cR and aR,cR conform-
ers. The cis and trans isomers of the cyclopentanol-based deriva-
tives of Group A were recommended as bR,cS and bR,cR
enantiomers. Those belonging to Group B were selected as bS,cR
and bR,cR enantiomers. Lactam- and imide-based molecules were
Figure 1. Chemical structure of the ligands BMY-7378, WAY-100635 and the related a1-ADR and 5-HT1A affinity values.
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Table 1. Chemical structures of compounds 1–42 (Group A).
n
R1 N
Y
R3
R2
Comp. R1 
n R2 
Y R3 
5-HT1A 
pKi 
α-1D 
pKi
1 1 H -CH2CH2O- 8.45  8.37 
2 1 H -CH2CH2O- 9.22 8.65 
3 1 CH3 -CH2CH2O- 6.32 6.06 
4 cis 
 
1 H -CH2CH2O- 5.93 7.09 
5 trans 1 H -CH2CH2O- 5.70 6.94 
6 1 H -CH2CH2S- 7.03 6.87 
7 
 
1 H -CH2CH2NH- 6.56 6.49 
8 
 
1 H -CH2CH2CH2- 8.56 6.28 
9 1 H -CH2CH2CH2- 
O
8.10 6.86 
10 1 H -CH2CH2O- 7.33 6.49 
O
O
O
O
O
O
O
O
O
O
OH
H
O
O
O
O
O
O
O
O
O
O
11 
 
1 H -CH2CH2O- 7.34 6.69 
12 
 
1 H -CH2CH2O- 8.58 6.61 
13 
 
1 H -CH2CH2O- 7.01 6.90 
14 
 
1 H -CH2CH2O- <6 6.77 
15 
 
1 H -CH2CH2O- 8.12 6.64 
16 1 H -CH2CH2O- 8.99 8.68 
O
O
O
O
O
O
S
O
O
O
 
O
O
O
O
O O
O
O
O
O
(continued)
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Table 1. Continued
Comp. R1 
n R2 
Y R3 
5-HT1A 
pKi 
α-1D 
pKi
 
19 
 
1 H -CH2CH2O- 
O
9.89 7.50 
20 
 
1 H CH2CH2O- 8.61 7.05 
21 
 
1 H -CH2CH2CH2- 8.00 6.36 
22 
 
1 H -CH2CH2O- 8.66 6.10 
23 
 
1 H -CH2CH2O- 7.54 < 5 
S
S
S
S
S
O
O
O
O
S
24 1 H -CH2CH2O- <6 5.08
25 1 H -CH2CH2O- 9.05 7.91
26 1 H -CH2CH2O-
8.08 6.77
27 1 H -CH2CH2O- 8.77 7.59
28 1 H -CH2CH2O- 7.98 6.30
29 cis 1 H -CH2CH2O- 8.03 6.88
30 trans 1 H -CH2CH2O- 8.02 6.86
31 1 H -CH2CH2O- 8.46 6.54
32 trans 1 H -CH2CH2O- 9.49 8.42
33 1 H -CH2CH2O- 9.08 8.09
17 
 
1 H CH2CH2O- 8.55 7.37 
18 1 H -CH2CH2CH2- 8.72 6.66 
O
O
S
S
 
(continued)
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chosen as aR,cS isomers, while spiro-derivatives were preferred as
aR,cR.
Consequently, in order to apply a common and homogeneous
protocol, for all the dataset compounds we assigned the 5-HT1A
pKi of the racemic mixture to the preferred enantiomers.
The followed alignment process considered the existing differ-
ences in conformation due to the various flexibility of Group A
and B molecules. Initially, the most probable conformers of com-
pounds 2 and 43 (taken as references for Group A and B, respect-
ively) were superimposed using the rigid body alignment protocol
implemented in MOE. Therefore, the flexible alignment approach
of MOE was applied to guide a proper alignment of all the com-
pounds of each group on the already aligned derivatives, used as
rigid templates. Successively, the dataset was submitted to 3D-
QSAR analyses, including CoMFA25 and CoMSIA26 studies, by
Sybyl-X 1.0 software27.
3D-QSAR analyses
CoMFA and CoMSIA approaches were performed to better under-
stand especially how the steric and electrostatic parameters so as
the hydrophobic, H-bond acceptor and H-bond donor descriptors
could modulate the selectivity over a1D ADR (Model I) and the
affinity for 5-HT1A receptor (Model II) of the whole dataset here
proposed. Both the Models I and II were built considering the
selectivity-based weighted 5-HT1A pKi (Model I) and the experi-
mental 5-HT1A pKi (Model II) as the dependent variables while the
different specific CoMFA and CoMSIA descriptors were taken into
account as independent ones.
In particular, for Model I, the ligand affinity towards the 5-HT1A
receptor has been re-calculated by taking into account the select-
ivity over a1D ADR, following a procedure we recently applied
around the development of selective PDE4B16 and PDE7
inhibitors21.
In this case, we considered the difference in pKi between the
5-HT1A and a1D ADR and the related ratio, obtaining a selectivity-
based weighted 5-HT1A pKi, according to Equations (1) and (2),
which are described as follows. Equation (1) was applied for those
compounds displaying higher or comparable a1D ADR and 5-HT1A
pKi while Equation (2) for the most selective 5-HT1A ligands.
Weighted 5-HT1A pKi ¼ 5-HT1A pKi  MR
þ ½ð5-HT1A pKi  a1D pKiÞ  MD
(1)
MR is the mean of the ratio between the 5-HT1A and the a1D
pKi values observed within all the molecules characterised by MR
values 1.0 and MD the mean of the difference between the
5-HT1A and the a1D pKi values of the same set of compounds.
Weighted 5-HT1A pKi ¼ 5-HT1A pKi
MRþ ½ð5-HT1A pKi-a1D pKiÞ MD0Þ
(2)
MR is the mean of the ratio between the 5-HT1A and the a1D
pKi values observed within all the molecules characterised by MR
spanning from 1.0 to 1.2 and MD’ the mean of the difference
Table 1. Continued
37 1 H -CH2CH2CH2CH2- 7.37 6.46
38 2 H -CH2CH2CH2- 7.24 6.65
39 1 H -CH2CH2O- 7.43 6.54
40 1 H -CH2CH2O- 6.90 7.31
41 1 H -CH2CH2O- 7.22 7.68
42 1 H -CH2CH2O- 6.96 7.12
Comp. R1 
n R2 
Y R3 
5-HT1A 
pKi 
α-1D 
pKi
34 E 1 H -CH2CH=CH- 7.63 6.68
35 1 H -CH2CH2- 7.32 6.53
36 1 H -CH2- <6 6.04
218 S. GUARIENTO ET AL.
Table 2. Chemical structure of compounds 43–91 (Group B).
N N
R1
O
Comp. R1
pKi Com
p. R1
pKi
5-
HT1A
α-1D α-1D5-
HT1A
43 7.64 8.14 68 6.93 n.d.
44 cis 7.52 8.11 69 7.09 7.20
45 
trans 7.63 7.86 70 6.80 6.89
46 cis 7.31 7.54 71 7.84 8.60
47 
trans 8.75 8.16 72 7.80 7.43
48 cis 7.73 7.80 73 8.05 6.87
49 
trans 8.22 7.55 74 7.23 7.45
50 8.26 7.52 75 7.30 7.29
51 8.18 7.33 76 7.69 7.02
52 8.46 6.43 77 7.44 6.71
53 cis 9.25 7.21 78 7.37 7.38
54 
trans 9.10 6.82 79 7.19 6.48
55 
trans 7.95 7.43 80 6.49 7.50
(continued)
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Table 2. Continued
Comp. R1
pKi Com
p. R1
pKi
5-
HT1A
α-1D α-1D5-
HT1A
57 
trans 8.14 7.75 82 7.28 7.05
58 cis 8.25 7.57 83 7.57 6.96
59 cis 8.29 6.42 84 7.36 7.98
60 
trans 7.59 7.78 85 7.61 8.02
61 cis 8.50 6.19 86 7.16 7.36
62 
trans 7.35 7.57 87 7.43 7.37
63 cis 8.58 6.78 88 7.22 7.27
64 
trans 8.90 8.51 89 7.48 7.26
56 cis 8.16 6.79 81 6.84 7.18
65 8.29 7.88 90 7.10 7.29
66 7.33 7.33 91 7.06 6.53
67 8.03 6.84
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between the 5-HT1A and the a1D pKi values of the whole dataset.
For molecules displaying MR >1.2 this term is approximated
to 1.0.
Following this procedure, the variation of the weighted pKi val-
ues within the dataset concerns 5 log orders, being most of the
selective compounds endowed with a weighted pKi spanning
from 8.00 up to 10.00. Conversely, the unselective (or reversed
selective) molecules fall in the range of 5.00–8.00.
Notably, it is expected that such a weighted parameter could
be much more predictive of the ligand selectivity profile over the
a1D ADR subtype observed within the chemical space disclosed
around the whole dataset here investigated.
Training set and test set
Concerning Model I, the overall dataset was divided into a training
set (68 compounds), for model generation, and in a test set (22
compounds), for model validation, being compound 68 excluded
since it was nor evaluated for a1D ADR activity. For the develop-
ment of Model II, 73 and 18 molecules were assigned to the train-
ing set and the test set, respectively.
For both the models, compounds were divided (in training and
the test sets) manually in order to include a representative range
of biological activities and structural variations of the starting
dataset and including in the test set at least 25% of the number
of training set molecules. Binding affinity values (pKi) range of the
compounds covered at least 4 log orders of magnitude.
CoMFA and CoMSIA models and statistical evaluation
CoMFA and CoMSIA methods are widely used 3D-QSAR techniques
which allow to relate any variation of an experimental parameter
(dependent variable) within a series of compounds with respect to
specific descriptors (independent variables). In details, the steric
and electrostatic fields and also the steric, electrostatic, hydropho-
bic, H-bond donor, H-bond acceptor ones were employed for
CoMFA and CoMSIA analyses, respectively. Starting from a proper
molecule alignment within a 3D cubic lattice (with a 2Å grid spac-
ing), the descriptor was calculated, using the standard Tripos force
field method. Successively, the derived model goodness and reli-
ability were evaluated using specific statistical tools, such as partial
least square (PLS) analysis and cross-validation methods.
Finally, the predictive ability concerning those compounds
belonging to the test set (r2pred) was also calculated, by means of
the following equation:
r2pred ¼ SDPRESSð Þ=SD
being SD and PRESS the sum of the squared deviations between
the biological activities of the test set molecules and the mean
activity of the training set compounds, and the squared deviation
between the observed and the predicted activities of the test set
compounds, respectively.
Any further detail concerning the (standard) CoMFA and CoMSIA
protocols and the related statistical and predictive evaluation we
applied were previously reported in a number of our works28–30.
Results
CoMFA and CoMSIA analyses here reported were used to explore,
through quantitative methods, the main features responsible of the
activity of an in-house library of 91 compounds as 5-HT1AR ligands,
and also of their related selectivity profile over a1D ADR
9–15.
As shown in Figure 2, the whole dataset included molecules
displaying a basic nitrogen, incorporated in a linear (in particular
ethanolamine, cysteamine, ethylendiamine, methylamine, ethyl-
amine, propylamine, butylamine, allylamine) or piperazine moiety,
connecting a five-membered heterocycle or carbocycle (in particu-
lar dioxolane, 1,3-oxathiolane, 1,3-dithiolane, tetrahydrofurane,
cyclopentanone, cyclopentanol and spiro-dioxolane) bringing at
least a phenyl ring or a spiro appendage. The members of the
library were divided into two groups, A and B, depending on
whether the basic nitrogen is part of the flexible chain or is incor-
porated into the piperazine ring (Tables 1 and 2, respectively).
Energy minimisation and alignment of the dataset highlighted
a relevant difference in the preferred conformation between
Group A and B. In particular, for the molecules of Group A, a
U-shaped conformation was the energetically favoured one, while
a much more linear disposition was found for Group B compounds
(Supplemental data S1). On the overall alignment, we performed
two series of 3D-QSAR analyses.
In detail, the first CoMFA and CoMSIA study (Model I) was per-
formed around the selectivity profile over a1D using a weighted
pKi (as described in the experimental section) while the second
one analysed 5HT1A potency trend using the ligands experimental
5-HT1A affinity values (Model II).
3D-QSAR analyses
Concerning Model I CoMFA and CoMSIA analyses were performed
by dividing compounds 1–91 excluding 68 into a training set for
Figure 2. Schematic representation of the library members.
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model generation and into a test set for model validation (see
Methods section). A graphical distribution of the selectivity (green
dots) and affinity profile (blue dots) of the dataset compounds is
shown in Figure 3.
Model II CoMFA and CoMSIA studies were calculated including
sixty-eight derivatives into the training set and choosing the other
molecules for the test set.
All statistical parameters supporting the two series of 3D-QSAR
analyses (Models I and II) are reported in Table 3 and detailed as
follows.
The final Model I CoMFA was generated by employing non-
cross-validated PLS analysis with the optimum number of compo-
nents (ONC¼ 7) to give a non-cross validated r2 (r2ncv)¼ 0.94, a
test set r2 (r2pred)¼ 0.80, standard error of estimate (SEE)¼ 0.278,
steric contribution ¼ 0.678 and electrostatic contribution ¼ 0.322.
The related CoMSIA analysis was derived using a statistical PLS
analysis leading to the following results: ONC¼ 6, a non-cross vali-
dated r2 (r2ncv)¼ 0.93, a test set r2 (r2pred)¼ 0.79, SEE¼ 0.312, steric
contribution¼ 0.173, electrostatic contribution¼ 0.139, hydropho-
bic contribution¼ 0.358, H-bond acceptor ¼ 0.213 and H-bond
donor ¼0.117.
An overall overview of the predictive ability of Model I study
can be obtained from graphical distributions of the predicted
weighted pKi values of the training set (blue dots) and test com-
pounds (red dots), as shown in Figure 4. The corresponding
experimental-based and predicted pKi values are reported as
Supplemental data S2 and S3.
The selected CoMFA Model II was generated by employing
non-cross-validated PLS analysis with the ONC¼ 6 to give a non-
cross validated r2 (r2ncv)¼ .92, a test set r2 (r2pred)¼ .78, SEE ¼
0.294, steric contribution ¼ 0.644 and electrostatic contribution ¼
0.356. The CoMSIA Model II was obtained with the following statis-
tical results: ONC ¼ 6, a non-cross validated r2 (r2ncv)¼ .91, a test
set r2 (r2pred)¼ .77, SEE¼ 0.280, steric contribution¼ 0.175,
electrostatic contribution¼ 0.155, hydrophobic contribution ¼
0.352, H-bond acceptor¼ 0.214 and H-bond donor¼ 0.104.
The derived distributions of the predicted pKi values of the
training set and test compounds are depicted in Figure 5 while
the specific experimental and predicted affinity values are
reported as Supplemental data S4 and S5.
Discussion
CoMFA and CoMSIA contour maps
Notably, for both the Models I and II, the CoMFA steric map
descriptors underlines through green polyhedra those areas which
prove to be favourable in terms of steric hindered substitutions,
while yellow maps highlight regions where bulky decorations
impaired the 5-HT1A selectivity (for Model I) or affinity (for Model
II) profile. The CoMFA electrostatic descriptors are shown as blue
Figure 3. Distribution of the experimental-based weighted affinity and of the experimental ones of the dataset compounds.
Table 3. Summary of CoMFA and CoMSIA analyses calculated as Models I and II.
Model I Model II
CoMFA CoMSIA CoMFA CoMSIA
No. compounds 68 68 73 73
Optimal number of components (ONC) 7 6 6 6
Leave one out r2 (r2loo) 0.60 0.58 0.62 0.55
Cross-validated r2 (r2cv) 0.75 0.74 0.73 0.71
Std. error of estimate (SEE) 0.278 0.312 0.294 0.280
Non cross-validated r2 (r2ncv) 0.94 0.93 0.92 0.91
F-value 101.014 65.725 87.006 64.876
Steric contribution 0.678 0.173 0.644 0.175
Electrostatic contribution 0.322 0.139 0.356 0.155
H-bond acceptor contribution – 0.213 – 0.214
H-bond donor contribution – 0.117 – 0.104
Hydrophobicity contribution – 0.358 – 0.352
Bootstrap r2 (r2boot) 0.97 0.95 0.94 0.93
Standard error of estimate r2boot (SEE r
2
boot) 0.268 0.271 0.250 0.280
Test set r2 (r2pred) 0.80 0.79 0.78 0.77
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areas around regions which tolerate electropositive groups, while
red polyhedra occupy any area where electronegative groups
enhance the selectivity (or affinity) towards the target.
Concerning CoMSIA analyses, the yellow and white hydropho-
bic contours suggest the insertion of lipophilic and polar groups,
respectively.
Finally, the introduction of H-bond acceptor and H-bond donor
moieties is encouraged or discouraged by magenta and cyan and
green (or red for Model II) and purple polyhedral, respectively.
Model I (5HT1A ligand selectivity over a1D ADR)
Based on an overall analysis of the CoMFA steric map, it could be
observed that those compounds belonging to Group A much
more properly fit the contour map, rather than the Group B ana-
logues (see Figure 6(a) and (b)). Indeed, the presence of a flexible
linker allows to arrange R1 of Group A compounds in proximity of
a large favoured green area, while the piperazine ring of Group B
moves this substituent to a quite switched positioning.
As a consequence, for Group A the diphenyl-substituted deriva-
tives are adequately projected towards the aforementioned large
green area, and also close to a second small one, while the spiro-
derivatives 40–42 fall in a disfavoured yellow area (Figure 6(a)).
Accordingly, most of the diphenyl-substituted compounds
1–38 are characterised by an acceptable selectivity profile, while
spiro-derivatives led sometimes to a reversed potency trend [see
40 (5-HT1A pKi¼ 6.90, a1D pKi¼ 7.31) 41 (5-HT1A pKi¼ 7.22, a1D pKi
¼ 7.68), 42 (5-HT1A pKi¼ 6.96, a1D pKi¼ 7.12)]. Nevertheless, spiro-
compounds could be optimised in selectivity by proper further
Figure 4. Distribution of the predicted weighted pKi values (p-w. pKi) with respect to the experimental-based pKi (e-w. pKi) of the training set compounds and of the
test set compounds according to Model I CoMFA (a) and CoMSIA (b) analyses.
Figure 5. Distribution of the predicted pKi values of training set compounds and of the test set compounds with respect to the experimental data according to Model
II CoMFA (a) and CoMSIA (b) analyses.
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decoration, such as those described within Group B (see com-
pounds 68–78) including bulky H-bond acceptor moeityies,
gaining new contacts with the green map.
Furthermore, the presence of a proper linker Y, as a propyl
chain, optimises the overall flexibility of the molecule and
allow the terminal phenyl ring and also R1 to better overlap
the favoured steric contours. Consequently, compounds 8
(Y¼ -CH2CH2CH2-; 5-HT1A pKi¼ 8.56, a1D pKi¼ 6.28), 9 (Y¼
-CH2CH2CH2-; 5-HT1A pKi¼ 8.10, a1D pKi¼ 6.86) and 18 (Y¼
-CH2CH2CH2-; 5-HT1A pKi¼ 8.72, a1D pKi¼ 6.66) result to be much
more selective than the analogues 1 (Y¼ -CH2CH2O-; 5-HT1A
pKi¼ 8.45, a1D pKi¼ 8.37), 2 (Y¼ -CH2CH2O-; 5-HT1A pKi¼ 9.22, a1D
pKi¼ 8.65) and 17 (Y¼ -CH2CH2O-; 5-HT1A pKi¼ 8.55, a1D
pKi¼ 7.37), respectively.
Interestingly, the ligand selectivity does not take advantage
from the introduction of any decoration onto the terminal phenyl
ring ortho positions. Indeed, moving from 8 (R3¼phenyl-; 5-HT1A
pKi¼ 8.56, a1D pKi¼ 6.28) and 20 (R3¼phenyl-; 5-HT1A pKi¼ 8.61,
a1D pKi¼ 7.05) to the 2-methoxy-substituted congeners 9
(R3¼ 2-methoxyphenyl-; 5-HT1A pKi¼ 8.10, a1D pKi¼ 6.86) and 19
(R3¼ 2-methoxyphenyl-; 5-HT1A pKi¼ 9.89, a1D pKi¼ 7.50), the lig-
and affinity trend reverses or increases towards both the receptors.
This information is also supported by the biological results obtained
for 26 (R3¼ 2-methylphenyl-; 5-HT1A pKi¼ 8.08, a1D pKi¼ 6.77), 25
(R3¼ 2-ethoxyphenyl-; 5-HT1A pKi¼ 9.05, a1D pKi¼ 7.91) and 27
(R3¼ 2-isopropoxyphenyl-; 5-HT1A pKi¼ 8.77, a1D pKi¼ 7.59).
Concerning the Group B compounds, the piperazine ring con-
strains the R1 substituent to be oriented towards a disfavoured
yellow area, leading most of the ligands far from the green one
(Figure 6(b)). In particular, the spiro-substitution is the one
that much more deeply impairs the selectivity within the group,
as exemplified by 75–77 (5-HT1A pKi¼ 7.30–7.44, a1D
pKi¼ 6.71–7.29)], with a poor selectivity profile for 5HT1-R over
ADR-a1D, whilst sometimes it results also reversed [see 69–71 (5-
HT1A pKi¼ 6.80–7.84, a1D pKi¼ 6.89–8.60) and 84–86 (5-HT1A
pKi¼ 7.16–7.61, a1D pKi¼ 7.37–8.02)].
Then, only the (potentially small) mono-substituted derivatives
are those that appear fitting a green polyhedron. On the other
hand, it should be noticed that the choice of introducing a lactam
or imide moiety linked to the R1 five-membered ring could pro-
vide for a better overall flexibility. In particular, the related cis
isomers, rather than the trans ones, achieve a conformation to effi-
ciently contact the steric map. The reliability of this information
can be verified comparing the selectivity profile of the cis con-
formers 56, 58, 59, 61, 63 (5-HT1A pKi¼ 8.16–8.58, a1D
pKi¼ 6.19–7.57) with those of trans ones 55, 57, 60, 62, 64
(5-HT1A pKi¼ 7.35–8.90, a1D pKi¼ 7.43–8.51).
As shown in Figure 6(c) and (d), the electrostatic contour
map reveals favoured region with the introduction of electro-
negative groups (red polyhedral) in the area surrounding the
spiro-derivatives and the diphenyl-substituted ones of Group A,
also suggesting the presence of electropositive portions for
bulkier groups in R1 (blue area). Interestingly, these results
allow to point out the introduction of electro-withdrawing
groups onto the spiro-derivatives or the development of
Figure 6. Contour map of Model I CoMFA steric regions are shown around the compounds 12 and 39 (a) and 52, 67 (b) while those of the electrostatic map are shown
in (c) and (d).
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analogues bearing lactam or imide moieties, as displayed within
the Group B series.
On the other hand, a small blue area placed around oxygen
atom of the linker Y in compounds 12 and 39 (Figure 6(c))
strongly confirms the beneficial role played by the propyl chain at
this position (rather than the ethoxy one).
A comparable electrostatic preferences profile can be described
for compounds belonging to Group B (see Figure 6(d)). Notably
these results are in good agreement with the privileged role
played by a lactam or imide moiety at the R1 five-membered ring,
as revealed by the steric map.
The steric and electrostatic maps obtained from CoMSIA ana-
lysis were in good agreement with those derived from the previ-
ous CoMFA study.
Hydrophobic moieties are beneficial (yellow map) around the
oxygen atom of tetrahydrofuran and near the corresponding het-
eroatom of the dioxolane, dithiolane and oxathionale derivatives,
while one disfavoured region (white map) falls around the cyclo-
pentanone or cyclopentanol functional moiety (Figure 7(a)).
Consequently, any kind of these five-membered rings appears to
have the proper polarity balance to encourage 5HT1A selectivity
of action.
Mono-substituted or diphenyl-substituted compounds of Group
B better surround the hydrophobic yellow map, than the spiro-
derivatives, which partially overlap the disfavoured white region
(Figure 7(b)). This contour map proves to be reached properly by
those compounds endowed with a flexible lactam or imide moi-
eties, being the cis isomers the most favoured (see also the infor-
mation coming from the steric map).
Magenta areas, favourable for H-bond acceptor moieties, are
located in proximity of the two phenyl rings of the disubstituted
derivatives of Groups A and B, being also highly overlapped by
any lactam and imide moieties in R1, and are placed also in prox-
imity of the spiro-derivatives of Group B (Supplemental data S6).
Finally, H-donor favoured regions (cyan polyhedral) are fulfilled by
the secondary amine nitrogen atom of the linker displayed within
Group A, but not by the piperazine tertiary one (Supplemental
data S7). Thus, the flexible linker is confirmed as the better choice
to ameliorate the selectivity issue.
Model II (5HT1A ligand affinity)
Since the first aim in the development of new 5HT1A ligands is the
design of compounds with an improved affinity profile, the
description of Model II results was organised in four sections,
based on the various substitutions displayed by the molecules of
interest: (i) part 1, including all the substitutions on the quaternary
carbon atom of the five-membered ring; (ii) part 2, consisting of
the five-membered ring (R1); (iii) part 3, formed by the linker Y;
(iv) part 4, represented by the terminal aromatic ring (R3).
The derived Model II CoMFA and CoMSIA maps were reported
in Charts 1 and 2, respectively. Only the CoMSIA hydrophobic, H-
bond acceptor and H-bond donor descriptors were reported, since
the steric and the electrostatic ones were highly similar to those
shown for the related CoMFA study. In any case, the contour areas
were depicted around compounds 19, 39 and 53 cis, 67 to repre-
sent Group A and B ligands, respectively.
Part 1
A favourable steric and hydrophobic polyhedra is detected in the
centre of the area occupied by Part1 of the scaffold, which proved
to be differently fitted by Group A and B derivatives because of
the different conformer positioning of the flexible or the rigid link-
ers, respectively.
Thus, the affinity profile of mono-substituted, di-substituted
and spiro-substituted compounds follows a different trend within
the two groups. Indeed, within Group A, the mono-phenyl substi-
tution is the most detrimental with respect to the di-phenyl and
spiro-analogues, poorly satisfying the aforementioned contour
maps. In addition, the insertion of a spiro or (spiro)anellated cycle
results to be tolerated, being these compounds able to occupy
partially the favoured steric areas and fully the hydrophobic map.
Nevertheless, the (spiro)anellated 40–42 (pKi¼ 6.90–7.22) display a
lower 5HT1A affinity profile, if compared with the di-substituted
derivatives. Indeed, the di-substituted derivatives of Group A suc-
cessfully overlap the aforementioned steric and hydrophobic
regions, as confirmed by the adequate affinity profile of most of
them (see 25–33; pKi¼ 7.98–9.49), pointing out this kind of substi-
tution as the most effective within Group A. In particular, this con-
clusion can be confirmed especially comparing compound 1
(pKi¼ 8.45) to 42 (pKi¼ 6.96).
Finally, a consistent H-bond acceptor favourable area surrounds
the part 1 of all these derivatives, suggesting a beneficial role
potentially due to the introduction of proper H-bonding functions
at this molecule portion.
Concerning Group B, the rigid linker constrains the ligand con-
formation to be arranged in a different and overall more effective
positioning, which allows the part 1 of the molecule to better con-
tact the contour maps. Thus, the di-substituted compounds
Figure 7. Model I CoMSIA hydrophobic favoured and disfavoured (white area) regions are shown around 12 and 39 (a) and 52, 67 (b). The compounds are displayed in
ball and stick mode.
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maintain an adequate ability to fit the CoMFA steric map, as previ-
ously discussed within the Group A analogues. In addition, also
the mono-substituted- and the spiro-derivatives of Group B are
much more properly oriented towards favoured steric and hydro-
phobic areas, as confirmed by the high affinity values of com-
pounds 44–49 (pKi¼ 7.31–8.75) and 67 (pKi¼ 8.03).
Nonetheless, only small decorations on the spirocycle part 1
are tolerated, as shown by 71–91 (pKi¼ 6.49–7.84), which have
lower 5HT1A affinity than 67 (pKi¼ 8.03).
In addition, for the mono-substituted analogues, a privileged
trend involving the trans isomers rather than the cis ones is high-
lighted [compare 48 cis (pKi¼7.73) with 49 trans (pKi¼ 8.22)].
Regarding the di-substituted compounds, CoMFA maps pro-
moted the insertion of a hydrophobic and electronegative decor-
ation in part 1 in the case of trans conformers, while
electropositive and polar moieties are recommended for the cis
ones. Accordingly, for the imide and lactam derivatives of the
dataset the cis isomer was preferred rather than the trans one,
even if both showing good pKi value [e.g. compare compounds
55 trans (pKi¼ 7.95), 57 trans (pKi¼8.14), 60 trans (pKi¼7.59), 62
trans (pKi¼ 7.35), with the related isomers 56 cis (pKi¼ 8.16), 58
cis (pKi¼8.25), 59 cis (pKi¼8.29), 61 cis (pKi¼ 8.50)]. In addition,
an overall positive role played by the imide and lactam moieties is
confirmed by an extended H-bond acceptor favoured area
(magenta polyhedral) involving part 1.
Part 2
As regard the five-membered ring of the scaffold, 3D-QSAR analy-
ses identify several defined features related to 5HT1A binding affin-
ity. For both the Groups A and B, CoMFA maps promote the
introduction of substituent onto the atom connecting part 1 and
part 3, in particular bearing electronegative groups, while the
CoMSIA contours discourages any putative H-bond acceptor moi-
ety around the whole five-membered ring. Interestingly, these
information prove to be consistent with the higher affinity trend
Chart 1. Contour maps of Model II CoMFA model steric and electrostatic regions are shown for Group A 19, 39 and Group B 53 cis, 67.
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Chart 2. Contour maps of Model II CoMSIA model hydrophobic, H-bond acceptor and H-bond donor descriptors are shown. Compounds 19, 39 and 53 cis, 67 are
depicted.
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observed within the cyclopentyloxy derivatives rather than that
about the cyclopentanone ones
Notably, the five-membered ring of Group A derivatives highly
fit the CoMSIA hydrophobic map, while the Group B counterparts
are arranged in a slightly different conformation due to the rigid
piperazine linker, preventing to fully overlap the aforementioned
contour.
Based on an overall perspective of these results, the dithiolane
ring appears to be the most adequate one for Group A, fully satis-
fying the aforementioned maps, as confirmed by higher affinity
values of 19 (pKi¼ 9.89) and 20 (pKi¼ 8.61) if compared with 12
(pKi¼ 8.58) and 1 (pKi¼ 8.45), respectively. Concerning Group B,
the replacement of the dioxolane core with the oxathiolane or
dithiolane ones is anyway allowed, [see the higher affinity values
of 50 (pKi¼ 8.26) and 51 (pKi¼ 8.18) with respect to 43
(pKi¼ 7.64)].
Finally, the cyclopentanole ring exhibits a balanced lipophilicity
profile and, particularly for Group B, results to properly satisfy the
suggested CoMFA steric and electrostatic requirements, as verified
by the effective cyclopentanole-based derivatives 53 cis
(pKi¼ 9.25) and 54 trans (pKi¼ 9.10).
Part 3
The most relevant result of the 3D QSAR analysis about this part
of the scaffold is the most positive steric effect of the open
linker rather than the piperazine on 5HT1A affinity. Bulky substitu-
tion at the linker level as well as the presence of an additional
substitution on the secondary amine seems to be poorly and
not allowed by the contours, as confirmed by the different affinity
profiles of compounds 1 (pKi¼ 8.45) and 43 (pKi¼ 7.64). In par-
ticular, the propylamine linker is tolerated, while longer or shorter
carbon chains are embedded in an electronegative region at dif-
ferent levels, lowering the compound affinity for the target
[see 35 (Y¼ –CH2CH2–; pKi¼ 7.32), 36 (Y¼ –CH2–; pKi< 6) and 37
(Y¼ –CH2CH2 CH2CH2–; pKi¼ 7.37)]. Finally, the encouraging effect
of the secondary amine rather than the tertiary one is described
by the presence of a close favoured H-donor contour that matches
one of the two hydrogen of the amine linker of Group A
derivatives.
Part 4
All the fields considered by CoMFA and CoMSIA studies reveal a
positive role played by the 2-methoxyphenyl ring around the
Group A derivatives. More in details, an electronegative contour
(red polyhedral) close to one of the two ortho positions of the
phenyl ring in R3 denotes the alkoxy decoration as a suitable
choice to improve the affinity for the 5HT1A receptor. This conclu-
sion is also underlined by the presence of polar, unfavourable H-
bond donor and favourable H-bond acceptor polyhedra in proxim-
ity of part 4.
On the other hand, a favourable steric polyhedron, surrounded
by unfavourable contours, suggested that the insertion of bulkier
substitutions than the methoxy one could impair the ligand affin-
ity, making the methoxy group the most effective alkoxy moiety
to be exploited.
This result may be verified by the decreasing affinity trend
moving from compounds 2 (R3¼ 2-methoxyphenyl; pKi¼ 9.22), 25
Chart 3. Superimpositions of the in-house derivative 63 cis and the external set compounds 93, 95 and 97 are depicted. The chemical structure and the 5-HT1A affinity
values for 92–97 are also shown.
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(R3¼ 2-ethoxyphenyl; pKi¼ 9.05) and 27 (R3¼ 2-isopropoxyphenyl;
pKi¼ 8.77) to the biaryl analogue 22 (pKi¼ 8.66).
Notably, the introduction of further groups in meta and para
positions of the R3 phenyl ring was discouraged by the steric field.
In particular, any structural modification including fused ring
systems such as naphthyl moieties, or meta and/or para (di)substi-
tuted derivatives led to less active compounds.
For Group B compounds, less information were available since
no example of compound with an un-substituted phenyl ring was
collected by our “in-house” library of molecules.
Taking into account an overall perspective of Model I and II
studies, the selection of an open linker rather than the piperazine
seems to be the most effective for both affinity and selectivity,
while piperazine derivatives could be further optimised through
the introduction of a longer chain (than the methylene) connect-
ing with the terminal phenyl ring.
In details, the selectivity issue seems to be related to an
adequate flexibility profile of the molecule.
Thus, the design of novel ligands bearing a flexible linker
combined with a diphenyl substitution or a proper branched
decoration enriched with polar moieties such as the lactam and
imide moieties onto the five-membered ring may derive new
more selective compounds. Spiro-derivatives may be optimised
by linking them to linear or to cyclic amine spacers and selecting
additional polar functions as decoration for the spiro-group or
longer linker including the basic core.
Notably, selectivity does not take advantage from the introduc-
tion of decorations onto the terminal phenyl ring, conversely to
the results obtained around the 5-HT1A affinity profile. In addition,
while the presence of cyclopentanone and of dithiolane as five-
membered rings is overall encouraged by Model II, only the dithio-
lane one (or generally a hydrophobic group) is the most recom-
mended for selectivity (Model I).
It should be observed that the derived data are in harmony
with the affinity and selectivity of reference compounds BMY-
7378 and WAY-100635, which exhibit longer aliphatic chains
connected to the piperazine ring in tandem with a 2-methoxy
substitution onto the terminal phenyl ring. In particular, our
observations about the decorations on the terminal phenyl
ring are consistent with the high affinity but poor selectivity of
the two.
Finally, in order to gain a qualitative validation of the results
here discussed, we also evaluated the ability of Model II contour
maps to rationalise the effectiveness of an external series of novel
(pyperazinyl)alkyl-based 5-HT1A ligands
31. In particular, these com-
pounds included a 1,3-dimethyl-purine-2,6-dione heterocycle as
bio-isostere of R1 substituent of the in-house compounds included
in Group B.
As shown in Chart 3, structural similarity-based alignments of
compounds 92–97 onto compound 63 cis reveal that only a few
number of these compounds are able to satisfy the requirements
pointed out by Model II. Indeed, 93 only partially mimic through
the purine-2,6-dione cycle the role played by the disubstituted
dioxolane ring of 63 cis, therefore displaying a lower pKi value.
Similarly, the related analogue 92, unsubstitued onto the ter-
minal phenyl moiety, proved to be poorly active as 5-HT1A ligand
lacking of proper contacts with the Model II steric map.
Conversely, those derivatives exhibiting a butyl (94, 95) or a pen-
tyl (96, 97) chain between the purine-2,6-dione and the pipera-
zine spacer are able to fulfil the specific features highlighted by
the Model II CoMFA steric and CoMSIA hydrophobic maps.
Indeed, the aliphatic linker simulate the dioxolane of 63 cis (and
also the much more hydrophobic dithiolane ring we previously
suggested), while the purine-based group is highly able to
reproduce the decoration enriched with polar moieties recom-
mended in R1 by 3D-QSAR studies.
Conclusions
The computational studies here presented highlight and discuss
the role played by the steric, electrostatic, H-bond donor, H-bond
acceptor and hydrophobic features of a number of chemical scaf-
folds included in an in-house library of 5-HT1A ligands. The results
coming from Model I and II CoMFA and CoMSIA studies reveal
useful suggestions for the further design of new chemical entities,
and are also able to predict their affinity and selectivity profiles
prior to synthesis.
In particular, despite the fact that the two group compounds
showed different conformations and occupation of the 3D-QSAR
contour maps, the introduction of lactame and imide decorations
attempted only for Group B resulted to be beneficial (also in terms
of selectivity) within the whole dataset. This kind of substitution is
highly encouraged as well as the choice of a proper flexible linker
connecting the terminal aromatic ring with an hydrophobic core
enriched with polar and H-bond acceptor functions.
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